Bridget A. Ross Sells 5,500 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 5,500 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $77.99, for a total value of $428,945.00. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $177,661.22. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LeMaitre Vascular Stock Down 0.8 %

LMAT opened at $78.75 on Wednesday. The business’s fifty day simple moving average is $68.12 and its 200 day simple moving average is $61.11. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $79.53. The stock has a market cap of $1.77 billion, a PE ratio of 52.27, a P/E/G ratio of 2.39 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. The firm had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.27 EPS. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.78 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.81%. LeMaitre Vascular’s payout ratio is 42.38%.

Analysts Set New Price Targets

LMAT has been the topic of a number of recent analyst reports. Barrington Research increased their price target on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. KeyCorp initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They issued a “sector weight” rating for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. JMP Securities increased their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research report on Friday, May 3rd. Finally, Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their target price for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $73.83.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently made changes to their positions in the business. YHB Investment Advisors Inc. purchased a new stake in LeMaitre Vascular during the first quarter valued at about $36,000. DekaBank Deutsche Girozentrale purchased a new stake in LeMaitre Vascular during the 3rd quarter valued at about $38,000. SRS Capital Advisors Inc. grew its position in LeMaitre Vascular by 325.5% during the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 524 shares during the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in LeMaitre Vascular in the 1st quarter worth approximately $206,000. Finally, Whitegate Investment Counselors Inc. bought a new stake in LeMaitre Vascular in the first quarter valued at approximately $216,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.